Hematopoietic Stem Cell Transplantation
"Hematopoietic Stem Cell Transplantation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
| Descriptor ID |
D018380
|
| MeSH Number(s) |
E02.095.147.500.500.500 E04.936.225.687.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hematopoietic Stem Cell Transplantation".
Below are MeSH descriptors whose meaning is more specific than "Hematopoietic Stem Cell Transplantation".
This graph shows the total number of publications written about "Hematopoietic Stem Cell Transplantation" by people in this website by year, and whether "Hematopoietic Stem Cell Transplantation" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2023 | 5 | 1 | 6 |
| 2024 | 6 | 0 | 6 |
| 2025 | 3 | 2 | 5 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hematopoietic Stem Cell Transplantation" by people in Profiles.
-
Disability-Free Survival: A Novel Morbidity Endpoint for Older Adult Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2026 Jul; 32(7):877.e1-877.e11.
-
Myelofibrosis-associated extramedullary hematopoiesis: Insights into hepatic, pulmonary, and thrombotic complications. Blood Rev. 2026 Jan; 75:101355.
-
Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis. Bone Marrow Transplant. 2026 01; 61(1):82-91.
-
Outcomes after Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal Impairment. Transplant Cell Ther. 2025 Oct; 31(10):824.e1-824.e13.
-
Role of ROCK2 inhibitors in the treatment of chronic graft-versus-host disease. Expert Opin Investig Drugs. 2025 May; 34(5):391-400.
-
Impact of hyperhydration on fluid overload and hematopoietic cell transplant after post-transplant cyclophosphamide-based graft-versus-host-disease prophylaxis. Front Immunol. 2025; 16:1543099.
-
Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual disease. Bone Marrow Transplant. 2025 02; 60(2):165-174.
-
Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation. Leuk Res. 2024 10; 145:107565.
-
Hypomethylating Agents are Effective in Treatment for Relapsed Myelofibrosis After Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2024 11; 30(11):1091.e1-1091.e8.
-
Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settings. Bone Marrow Transplant. 2024 Nov; 59(11):1542-1551.